CSBio CSBio

X
[{"orgOrder":0,"company":"Sirion Biotech","sponsor":"PerkinElmer","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PerkinElmer\u2019s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Sirion Biotech"},{"orgOrder":0,"company":"Evotec","sponsor":"Sernova Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Sernova Announce Exclusive Strategic Partnership For iPSC-based Beta Cell Replacement Therapy to Advance a 'functional Cure' for Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Evotec"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The partnership leverages iPSC-based beta cells from Evotec’s QRbeta initiative. Evotec reliably produces human iPSC-based beta cells in islet-like clusters in a quality controlled (“QC”) scalable bioreactor process.

            Lead Product(s): iPSC-based Beta Cell Replacement Therapy

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Sernova Corp.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership May 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration combines SIRION’s adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy and expertise in viral vector development and production with CRG’s deep knowledge of genetic regulatory mechanisms.

            Lead Product(s): AAV-based Gene Therapy

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: PerkinElmer

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY